Table 2. Somatic mutations accompanied with PI3K/AKT pathway gene aberrations.
| Variables | WT (n=100) | PI3K/AKT pathway mutations# | p-value*† | p-value**† | |||
| PIK3CA-KD (n=36) | PIK3CA-HD (n=26) | PIK3CA-OD (n=10) | P/A (n=21) | ||||
| TP53 | 33 (32.0%) | 26 (72.2%) | 14 (53.9%) | 9 (90.0%) | 14 (66.7%) | <0.0001 | 0.14 |
| ERBB2 | 8 (8.0%) | 10 (27.8%) | 8 (30.8%) | 2 (20.0%) | 0 (0%) | 0.008 | 0.80 |
| FAT1 | 3 (3.0%) | 9 (25.0%) | 2 (7.7%) | 1 (10.0%) | 2 (9.5%) | 0.004 | 0.10 |
| ESR1 | 5 (5.0%) | 6 (16.7%) | 4 (15.4%) | 0 (0%) | 0 (0%) | 0.18 | 0.90 |
| DNMT3A | 6 (6.0%) | 7 (19.4%) | 0 (0%) | 2 (20.0%) | 2 (9.5%) | 0.15 | 0.04 |
| FGFR | 7 (7.0%) | 4 (11.1%) | 8 (36.4%) | 0 (0%) | 3 (14.3%) | 0.05 | 0.10 |
| NF1 | 4 (4.0%) | 1 (2.8%) | 5 (19.2%) | 1 (10.0%) | 0 (0%) | 0.36 | 0.07 |
| TMB-High | 5 (5.0%) | 8 (22.2%) | 14 (53.9%) | 3 (30.0%) | 4 (19.1%) | <0.0001 | 0.01 |
#Patients with PI3K/AKT pathway aberrations were divided into four groups: WT group, PIK3CA-KD group, PIK3CA-HD group, PIK3CA-OD group, and P/A (other PI3K/AKT pathway mutations) group.
p-values† were calculated using Student’s t-tests for continuous variables and using Chi-square tests (Mentel-Haenszel for >2 levels comparison), or Fisher’s exact tests (n<5) for categorical variables.
p-values* compared variables between WT patients and PI3K/AKT pathway aberrant patients; p-value** compared variables between PIK3CA-KD mutant patients and PIK3CA-HD mutant patients.